Study of Atezolizumab Plus Carboplatin and Etoposide With... | NCT04665856

Label	Type	Description	Intervention Names
Tiragolumab + Atezolizumab + Carboplatin and Etoposide	Experimental	Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.	Drug: Tiragolumab Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide
Placebo + Atezolizumab + Carboplatin and Etoposide	Placebo Comparator	Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles	Drug: Atezolizumab Drug: Carboplatin Drug: Etoposide Drug: Tiragolumab Matching Placebo

Name	Type	Description	Arm Group Labels	Other Names
Tiragolumab	Drug	Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.	Tiragolumab + Atezolizumab + Carboplatin and Etoposide

Measure	Description	Time Frame
Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set (PAS)	PFS was defined as time from randomization to the first occurrence of disease progression (PD), as assessed by the investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm).	Up to 32.3 months
Overall Survival (OS) in the PAS	OS was defined as the time from the date of randomization to the date of death from any cause.	Up to 32.3 months

Measure	Description	Time Frame
PFS in the FAS	PFS was defined as time from randomization to the first occurrence of PD, as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Name	Affiliation	Role
Clinical Trials	Hoffmann-La Roche	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Beijing Cancer Hospital		Beijing		100142	China
Beijing Chest Hospital

ID	Title	Description
FG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 milligrams (mg), followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target area under the concentration-time curve (AUC) of 5 milligrams per mililiter per minute (mg/mL/min) as an intravenous (IV) infusion, once every 3 weeks (Q3W), on Day 1 of each 21-day cycle along with etoposide, 100 milligrams per square meter (mg/m^2), as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Dec 14, 2023	Aug 26, 2025

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set (PAS)

PFS was defined as time from randomization to the first occurrence of disease progression (PD), as assessed by the investigator using Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm).

Primary Analysis Set (PAS) included all randomized participants without presence or history of brain metastases at baseline.

Posted

Median

95% Confidence Interval

months

Up to 32.3 months

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Units	Counts
Participants	OG00056 OG00154

Title

Denominators

Categories

Title	Measurements
	OG0005.39(4.30 to 6.77) OG0015.59(4.53 to 7.89)

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		Log Rank		0.0348	This study is a bridging study without formal testing, the p value here is descriptive.	Hazard Ratio (HR)	0.65			2-Sided	95	0.43	0.97					Superiority

Primary

Overall Survival (OS) in the PAS

OS was defined as the time from the date of randomization to the date of death from any cause.

PAS included all randomized participants without presence or history of brain metastases at baseline.

Posted

Median

95% Confidence Interval

months

Up to 32.3 months

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Secondary

PFS in the FAS

PFS was defined as time from randomization to the first occurrence of PD, as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

FAS included all randomized participants whether or not the participants received the assigned study treatment.

Posted

Median

95% Confidence Interval

months

Up to 32.3 months

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide

Secondary

OS in the FAS

OS was defined as the time from the date of randomization to the date of death from any cause.

FAS included all randomized participants whether or not the participants received the assigned study treatment.

Posted

Median

95% Confidence Interval

months

Up to 32.3 months

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Secondary

Investigator-Assessed Confirmed Objective Response Rate (ORR) in the PAS

ORR was defined as the percentage of participants with either a confirmed complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart as assessed by investigator according to RECIST v.1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters in the absence of CR. Percentages have been rounded off.

PAS included all randomized participants without presence or history of brain metastases at baseline.

Posted

Number

95% Confidence Interval

percentage of participants

Up to 32.3 months

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001

Secondary

Investigator-Assessed Confirmed ORR in the FAS

ORR was defined as the percentage of participants with either a confirmed CR or PR on two consecutive occasions ≥4 weeks apart as assessed by investigator according to RECIST v.1.1. CR was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters in the absence of CR. Percentages have been rounded off.

FAS included all randomized participants whether or not the participants received the assigned study treatment.

Posted

Number

95% Confidence Interval

percentage of participants

Up to 32.3 months

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide

Secondary

Investigator-Assessed Duration of Response (DOR) in the PAS

DOR was defined as the time interval from the date of the first occurrence of a confirmed objective response until the first date of PD as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurs first. DOR was evaluated for participants who had an objective response of CR or PR. CR was defined as the disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

PAS included all randomized participants without presence or history of brain metastases at baseline. Overall number analyzed is the number of participants with objective response i.e., responders.

Posted

Median

95% Confidence Interval

months

Up to 32.3 months

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Secondary

Investigator-Assessed DOR in the FAS

FAS included all randomized participants whether or not the participants received the assigned study treatment. Overall number analyzed is the number of participants with objective response i.e., responders.

Posted

Median

95% Confidence Interval

months

Up to 32.3 months

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Secondary

Investigator-Assessed PFS Rates at 6 Months and 12 Months in the PAS

PFS = time from randomization to the first occurrence of PD, per investigator per RECIST v1.1/ death from any cause, whichever occurs first. PFS rate at 6 and 12 = the percentage of participants who have not experienced PD per investigator per RECIST v1.1/ death from any cause at 6 and 12 months. PD =at least a 20% increase in the sum of diameters of target lesions, taking as reference the SOD at prior timepoints (including baseline), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Kaplan-Meier (K-M) method was used to estimate PFS rate. Percentages have been rounded off. Abbreviation used in Statistical Analysis section - Event Free Rate - EFR. The event free rate (for example the inv-PFS free rate of 10.24% at 12-months) used the K-M approach to estimate, which accounts for the censoring, the specific nature of time-to-event data. Naive calculation based on patient proportion will introduce bias.

PAS included all randomized participants without presence or history of brain metastases at baseline. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available at the specified timepoint.

Posted

Number

95% Confidence Interval

percentage of participants

Month 6, Month 12

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Secondary

Investigator-Assessed PFS Rates at 6 Months and 12 Months in the FAS

PFS was defined as time from randomization to the first occurrence of PD, as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurs first. PFS rate at 6 months and 12 months defined as the percentage of participants who have not experienced PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 and 12 months. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints (including baseline), in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. K-M method was used to estimate PFS rate. Percentages have been rounded off. The event free rate used the K-M approach to estimate, which accounts for the censoring, the specific nature of time-to-event data. Naive calculation based on patient proportion will introduce bias.

FAS included all randomized participants whether or not the participants received the assigned study treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available at the specified timepoint.

Posted

Number

95% Confidence Interval

percentage of participants

Month 6, Month 12

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Secondary

Overall Survival Rate at 12 Months and 24 Months in the PAS

OS was defined as the time from the date of randomization to the date of death from any cause. OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months. Percentages have been rounded off.

PAS included all randomized participants without presence or history of brain metastases at baseline. Overall number of participants analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available at the specified timepoint.

Posted

Number

95% Confidence Interval

percentage of participants

Month 12, Month 24

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide

Secondary

Overall Survival Rates at 12 Months and 24 Months in the FAS

FAS included all randomized participants whether or not the participants received the assigned study treatment. Overall number of participants analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available at the specified timepoint.

Posted

Number

95% Confidence Interval

percentage of participants

Month 12, Month 24

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide

Secondary

Percentage of Participants With Adverse Events

An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An adverse event can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product, any new disease or exacerbation of an existing disease (a worsening in the character, frequency, or severity of a known condition), recurrence of an intermittent medical condition not present at baseline, any deterioration in a laboratory value or other clinical test that is associated with symptoms or leads to a change in study treatment or concomitant treatment or discontinuation from study drug or adverse events that are related to a protocol-mandated intervention, including those that occur prior to assignment of study treatment.

Not Posted

Apr 2026

Up to 66 months

Participants

Secondary

Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score in the PAS

Not Posted

Apr 2026

Up to approximately 66 months

Participants

Secondary

TTCD Assessed Using EORTC QLQ-C30 Score in the FAS

Not Posted

Apr 2026

Up to approximately 66 months

Participants

Secondary

Maximum Plasma Concentration (Cmax) of Tiragolumab

Only sparse pharmacokinetic samples were collected in this study. With the focus on only Cmax and Cmin, there are no additional PK timepoints not reported

PK-evaluable population included all participants who received at least one dose of tiragolumab treatment and who have at least one post-baseline PK sample available.

Posted

Geometric Mean

Geometric Coefficient of Variation

microgram per milliliter (μg/mL)

Cycle 1 Day 1, 30 mins post end of infusion (EOI) (cycle length= 21 days)

ID	Title	Description
OG000	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Units	Counts
Participants

Secondary

Minimum Plasma Concentration (Cmin) of Tiragolumab

PK-evaluable population included all participants who received at least one dose of tiragolumab treatment and who have at least one post-baseline PK sample available. Overall number of participants analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analyses at the specified timepoints.

Posted

Geometric Mean

Geometric Coefficient of Variation

μg/mL

Pre-dose, Day 1 of Cycles 2, 3, 4, 8, 12, 16 (cycle length= 21 days)

ID	Title	Description
OG000	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Units	Counts
Participants

Secondary

Cmax of Atezolizumab

Atezolizumab PK evaluable set included all participants who received at least one dose of atezolizumab treatment and who have at least one post-baseline PK sample available.

Posted

Geometric Mean

Geometric Coefficient of Variation

microgram per milliliter (μg/mL)

Cycle 1 Day 1, 30 mins post EOI (cycle length= 21 days)

ID	Title	Description
OG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Secondary

Cmin of Atezolizumab

Atezolizumab PK evaluable set included all participants who received at least one dose of atezolizumab treatment and who have at least one post-baseline PK sample available. Overall number of participants analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analyses at the specified timepoints.

Posted

Geometric Mean

Geometric Coefficient of Variation

μg/mL

Pre-dose, Day 1 of Cycles 2, 3, 4, 8, 12, 16 (cycle length= 21 days)

ID	Title	Description
OG000	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
OG001	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.

Secondary

Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab

Not Posted

Apr 2026

Predose on Day 1 of Cycles (each cycle=21 days) 1, 2, 3, 4, 8, 12, 16 and at TD visit (up to approximately 49 months)

Participants

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Febrile neutropenia	Blood and lymphatic system disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0012 events2 affected60 at risk
Myelosuppression	Blood and lymphatic system disorders	MedDRA version 26.0	Systematic Assessment	EG0004 events4 affected63 at risk EG0013 events3 affected60 at risk
Neutropenia	Blood and lymphatic system disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Thrombocytopenia	Blood and lymphatic system disorders	MedDRA version 26.0	Systematic Assessment	EG0002 events2 affected63 at risk EG0010 events0 affected60 at risk
Cardiac failure	Cardiac disorders	MedDRA version 26.0	Systematic Assessment	EG0002 events2 affected63 at risk EG0010 events0 affected60 at risk
Cardiac failure acute	Cardiac disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Goitre	Endocrine disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Hyperthyroidism	Endocrine disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Gastritis	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Intestinal polyp	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Pyrexia	General disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0012 events2 affected60 at risk
Hepatic function abnormal	Hepatobiliary disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Infection	Infections and infestations	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0012 events2 affected60 at risk
Infective exacerbation of bronchiectasis	Infections and infestations	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Pneumonia	Infections and infestations	MedDRA version 26.0	Systematic Assessment	EG0002 events2 affected63 at risk EG0014 events4 affected60 at risk
Upper respiratory tract infection	Infections and infestations	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Skull fractured base	Injury, poisoning and procedural complications	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Subdural haematoma	Injury, poisoning and procedural complications	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Neutrophil count decreased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0003 events3 affected63 at risk EG0011 events1 affected60 at risk
Platelet count decreased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0003 events3 affected63 at risk EG0015 events5 affected60 at risk
Hyperglycaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Hypokalaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Hyponatraemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0002 events1 affected63 at risk EG0012 events2 affected60 at risk
Ketoacidosis	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Type 2 diabetes mellitus	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Back pain	Musculoskeletal and connective tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Myositis	Musculoskeletal and connective tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Subarachnoid haemorrhage	Nervous system disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Renal failure	Renal and urinary disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Urinary retention	Renal and urinary disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0011 events1 affected60 at risk
Immune-mediated lung disease	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0002 events2 affected63 at risk EG0011 events1 affected60 at risk
Interstitial lung disease	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Obstructive airways disorder	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Pleural effusion	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Pneumonitis	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Respiratory failure	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Respiratory tract haemorrhage	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Dermatitis exfoliative	Skin and subcutaneous tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0010 events0 affected60 at risk
Rash	Skin and subcutaneous tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Pelvic venous thrombosis	Vascular disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk
Vena cava thrombosis	Vascular disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0011 events1 affected60 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA version 26.0	Systematic Assessment	EG000100 events56 affected63 at risk EG001122 events58 affected60 at risk
Leukopenia	Blood and lymphatic system disorders	MedDRA version 26.0	Systematic Assessment	EG00025 events10 affected63 at risk EG00129 events10 affected60 at risk
Neutropenia	Blood and lymphatic system disorders	MedDRA version 26.0	Systematic Assessment	EG00021 events8 affected63 at risk EG00130 events13 affected60 at risk
Thrombocytopenia	Blood and lymphatic system disorders	MedDRA version 26.0	Systematic Assessment	EG00010 events6 affected63 at risk EG00115 events9 affected60 at risk
Atrial fibrillation	Cardiac disorders	MedDRA version 26.0	Systematic Assessment	EG0004 events4 affected63 at risk EG0011 events1 affected60 at risk
Sinus tachycardia	Cardiac disorders	MedDRA version 26.0	Systematic Assessment	EG0004 events3 affected63 at risk EG0017 events4 affected60 at risk
Supraventricular extrasystoles	Cardiac disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0014 events4 affected60 at risk
Hyperthyroidism	Endocrine disorders	MedDRA version 26.0	Systematic Assessment	EG0003 events3 affected63 at risk EG0014 events3 affected60 at risk
Hypothyroidism	Endocrine disorders	MedDRA version 26.0	Systematic Assessment	EG0007 events7 affected63 at risk EG0018 events6 affected60 at risk
Abdominal distension	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0014 events4 affected60 at risk
Abdominal pain	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0013 events3 affected60 at risk
Constipation	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG00024 events19 affected63 at risk EG00119 events17 affected60 at risk
Diarrhoea	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG0006 events5 affected63 at risk EG0016 events5 affected60 at risk
Nausea	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG00017 events13 affected63 at risk EG00123 events15 affected60 at risk
Toothache	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0013 events3 affected60 at risk
Vomiting	Gastrointestinal disorders	MedDRA version 26.0	Systematic Assessment	EG0009 events9 affected63 at risk EG00112 events10 affected60 at risk
Asthenia	General disorders	MedDRA version 26.0	Systematic Assessment	EG0005 events4 affected63 at risk EG0014 events4 affected60 at risk
Chest discomfort	General disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0013 events3 affected60 at risk
Chest pain	General disorders	MedDRA version 26.0	Systematic Assessment	EG0003 events3 affected63 at risk EG0013 events3 affected60 at risk
Fatigue	General disorders	MedDRA version 26.0	Systematic Assessment	EG0003 events3 affected63 at risk EG00112 events10 affected60 at risk
Influenza like illness	General disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0014 events3 affected60 at risk
Malaise	General disorders	MedDRA version 26.0	Systematic Assessment	EG0004 events4 affected63 at risk EG0017 events7 affected60 at risk
Oedema peripheral	General disorders	MedDRA version 26.0	Systematic Assessment	EG0000 events0 affected63 at risk EG0013 events3 affected60 at risk
Pain	General disorders	MedDRA version 26.0	Systematic Assessment	EG0003 events3 affected63 at risk EG0013 events3 affected60 at risk
Pyrexia	General disorders	MedDRA version 26.0	Systematic Assessment	EG00011 events10 affected63 at risk EG00113 events10 affected60 at risk
Pneumonia	Infections and infestations	MedDRA version 26.0	Systematic Assessment	EG0009 events9 affected63 at risk EG0013 events3 affected60 at risk
Infusion related reaction	Injury, poisoning and procedural complications	MedDRA version 26.0	Systematic Assessment	EG0004 events4 affected63 at risk EG00115 events10 affected60 at risk
Alanine aminotransferase increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG00030 events18 affected63 at risk EG00137 events19 affected60 at risk
Aspartate aminotransferase increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG00025 events18 affected63 at risk EG00131 events14 affected60 at risk
Bilirubin conjugated increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0007 events4 affected63 at risk EG0015 events4 affected60 at risk
Blood alkaline phosphatase increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0008 events7 affected63 at risk EG00111 events7 affected60 at risk
Blood bilirubin increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG00012 events4 affected63 at risk EG0019 events5 affected60 at risk
Blood creatine phosphokinase increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0008 events4 affected63 at risk EG0014 events4 affected60 at risk
Blood creatinine increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0003 events2 affected63 at risk EG0015 events4 affected60 at risk
Blood lactate dehydrogenase increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG00013 events9 affected63 at risk EG00116 events12 affected60 at risk
Blood thyroid stimulating hormone increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0003 events3 affected63 at risk EG0014 events4 affected60 at risk
Blood uric acid increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0003 events2 affected63 at risk EG0013 events3 affected60 at risk
Electrocardiogram QT prolonged	Investigations	MedDRA version 26.0	Systematic Assessment	EG0004 events3 affected63 at risk EG0019 events4 affected60 at risk
Gamma-glutamyltransferase increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG00013 events10 affected63 at risk EG00113 events8 affected60 at risk
Lymphocyte count decreased	Investigations	MedDRA version 26.0	Systematic Assessment	EG00012 events6 affected63 at risk EG00137 events7 affected60 at risk
Neutrophil count decreased	Investigations	MedDRA version 26.0	Systematic Assessment	EG000101 events42 affected63 at risk EG001144 events44 affected60 at risk
Platelet count decreased	Investigations	MedDRA version 26.0	Systematic Assessment	EG00099 events40 affected63 at risk EG001134 events39 affected60 at risk
Weight decreased	Investigations	MedDRA version 26.0	Systematic Assessment	EG00013 events12 affected63 at risk EG0019 events9 affected60 at risk
Weight increased	Investigations	MedDRA version 26.0	Systematic Assessment	EG0005 events4 affected63 at risk EG0016 events6 affected60 at risk
White blood cell count decreased	Investigations	MedDRA version 26.0	Systematic Assessment	EG000105 events42 affected63 at risk EG001144 events42 affected60 at risk
Decreased appetite	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG00016 events14 affected63 at risk EG00115 events13 affected60 at risk
Hyperglycaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG00013 events8 affected63 at risk EG0017 events6 affected60 at risk
Hypertriglyceridaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0005 events4 affected63 at risk EG0014 events4 affected60 at risk
Hyperuricaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG00014 events8 affected63 at risk EG00115 events11 affected60 at risk
Hypoalbuminaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG00026 events16 affected63 at risk EG00131 events13 affected60 at risk
Hypocalcaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0002 events1 affected63 at risk EG00112 events4 affected60 at risk
Hypochloraemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0002 events2 affected63 at risk EG0016 events4 affected60 at risk
Hypokalaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0007 events5 affected63 at risk EG0019 events7 affected60 at risk
Hypomagnesaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0004 events3 affected63 at risk EG0016 events4 affected60 at risk
Hyponatraemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG00027 events19 affected63 at risk EG00120 events15 affected60 at risk
Hypophosphataemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0004 events4 affected63 at risk EG00110 events5 affected60 at risk
Hypoproteinaemia	Metabolism and nutrition disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0014 events4 affected60 at risk
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0016 events6 affected60 at risk
Back pain	Musculoskeletal and connective tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0014 events4 affected60 at risk
Insomnia	Psychiatric disorders	MedDRA version 26.0	Systematic Assessment	EG0006 events4 affected63 at risk EG0017 events6 affected60 at risk
Cough	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0008 events7 affected63 at risk EG00114 events12 affected60 at risk
Haemoptysis	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0013 events3 affected60 at risk
Productive cough	Respiratory, thoracic and mediastinal disorders	MedDRA version 26.0	Systematic Assessment	EG0005 events5 affected63 at risk EG0012 events2 affected60 at risk
Alopecia	Skin and subcutaneous tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0008 events8 affected63 at risk EG00121 events21 affected60 at risk
Pruritus	Skin and subcutaneous tissue disorders	MedDRA version 26.0	Systematic Assessment	EG0006 events6 affected63 at risk EG00114 events10 affected60 at risk
Rash	Skin and subcutaneous tissue disorders	MedDRA version 26.0	Systematic Assessment	EG00010 events9 affected63 at risk EG00125 events17 affected60 at risk
Hypertension	Vascular disorders	MedDRA version 26.0	Systematic Assessment	EG0001 events1 affected63 at risk EG0014 events4 affected60 at risk

ID	Term
D002283	Carcinoma, Bronchogenic
D001984	Bronchial Neoplasms
D008175	Lung Neoplasms
D012142	Respiratory Tract Neoplasms
D013899	Thoracic Neoplasms
D009371	Neoplasms by Site
D009369	Neoplasms
D008171	Lung Diseases
D012140	Respiratory Tract Diseases

ID	Term
D056831	Coordination Complexes
D009930	Organic Chemicals
D011034	Podophyllotoxin
D013764	Tetrahydronaphthalenes
D009281	Naphthalenes
D011084	Polycyclic Aromatic Hydrocarbons
D006841	Hydrocarbons, Aromatic
D006844	Hydrocarbons, Cyclic
D006838	Hydrocarbons
D011083	Polycyclic Compounds
D005960	Glucosides
D006027	Glycosides
D002241	Carbohydrates

ID	Title	Description
BG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
BG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.
BG002	Total	Total of all reporting groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Placebo + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, followed by tiragolumab matching placebo, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 of each 21-day cycle along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab matching placebo given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.	40	63	23	63	60	63
EG001	Tiragolumab + Atezolizumab + Carboplatin + Etoposide	Participants received atezolizumab, 1200 mg, tiragolumab, 600 mg, and carboplatin, at a dose targeting initial target AUC of 5 mg/mL/min as an IV infusion, Q3W, on Day 1 along with etoposide, 100 mg/m^2, as an IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles as induction treatment. (1 Cycle = 21 days). Participants then received maintenance treatment with atezolizumab, 1200 mg, followed by tiragolumab, 600 mg, given as an IV infusion, Q3W, from Day 1 of Cycle 5 until disease progression, loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression.	43	60	21	60	60	60

ID	Term
C000730814	Tiragolumab
C000594389	atezolizumab
D016190	Carboplatin
D005047	Etoposide